PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $95.00

PTC Therapeutics (NASDAQ:PTCT) had its price target boosted by stock analysts at TD Cowen from $90.00 to $95.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen‘s price target suggests a potential upside of 58.41% from the company’s current price.

A number of other analysts have also commented on PTCT. Royal Bank Of Canada boosted their target price on PTC Therapeutics from $75.00 to $77.00 and gave the company a “sector perform” rating in a research report on Friday. Wells Fargo & Company boosted their target price on shares of PTC Therapeutics from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday. Wall Street Zen cut PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 10th. Cantor Fitzgerald raised their price target on PTC Therapeutics from $130.00 to $137.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 22nd. Finally, Truist Financial started coverage on shares of PTC Therapeutics in a research report on Friday, October 16th. They issued a “hold” rating and a $62.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $95.64.

PTC Therapeutics Price Performance

PTCT stock traded down $4.49 during midday trading on Friday, reaching $59.97. The company had a trading volume of 2,347,947 shares, compared to its average volume of 1,348,979. The company has a market capitalization of $5.01 billion, a price-to-earnings ratio of -103.40, a price-to-earnings-growth ratio of 1.90 and a beta of 0.49. PTC Therapeutics has a 1-year low of $58.80 and a 1-year high of $90.87. The stock has a 50 day moving average price of $65.57 and a 200-day moving average price of $70.87.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The firm had revenue of $357.81 million during the quarter, compared to analysts’ expectations of $306.43 million. The company’s quarterly revenue was up 69.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.20 earnings per share. As a group, research analysts anticipate that PTC Therapeutics will post 1.19 earnings per share for the current year.

Insider Activity

In other PTC Therapeutics news, Director Michael Schmertzler sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $59.61, for a total value of $149,025.00. Following the completion of the sale, the director owned 1,291,594 shares of the company’s stock, valued at approximately $76,991,918.34. This trade represents a 0.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Mark Boulding sold 435 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $64.16, for a total value of $27,909.60. Following the completion of the sale, the vice president owned 105,272 shares in the company, valued at $6,754,251.52. The trade was a 0.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 77,370 shares of company stock worth $5,322,261. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of PTC Therapeutics

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in PTC Therapeutics in the second quarter valued at $1,139,089,000. Jupiter Topco LLC acquired a new stake in shares of PTC Therapeutics in the second quarter valued at approximately $590,182,000. Janus Henderson Group PLC lifted its holdings in PTC Therapeutics by 48.3% in the 1st quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock valued at $489,997,000 after purchasing an additional 2,342,101 shares in the last quarter. William Blair Investment Management LLC acquired a new stake in shares of PTC Therapeutics during the second quarter worth $140,520,000. Finally, Bank of America Corp DE acquired a new position in PTC Therapeutics during the second quarter worth approximately $118,462,000.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Analysts raised their price targets. Wells Fargo increased its target to $112 from $109 and maintained an “overweight” rating, while RBC raised its target to $77 from $75 but retained a “sector perform” rating. The new targets imply substantial potential upside from recent trading levels. Analyst price target changes
• Positive Sentiment: PTC raised its full-year 2026 outlook. The company now expects total revenue of $1.29 billion to $1.32 billion and product revenue of $960 million to $990 million. Third-quarter revenue reached approximately $358 million, up 69.6% year over year and well above the roughly $306 million consensus estimate. PTC Therapeutics third-quarter results
• Positive Sentiment: Sephience commercialization remained a major growth driver. The product generated $182 million in third-quarter revenue, supported by continued U.S. growth and international expansion. PTC also acquired ST-920, a Fabry disease gene therapy, and expects to complete its Biologics License Application submission in the fourth quarter of 2026.
• Neutral Sentiment: Analyst commentary and the earnings call highlighted strong operating performance and business expansion, but investors are likely to focus on whether the revenue growth can translate into sustainable earnings and cash flow. Third-quarter earnings call transcript
• Negative Sentiment: Profitability was the key disappointment. PTC reported a GAAP loss of $0.62 per share, versus consensus expectations for earnings of $0.14 per share. Although adjusted earnings were reported by some data providers at $0.61 per share, the headline GAAP loss and sharply lower year-over-year earnings likely pressured the stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.